title: Effects of captopril on myocardial protection during cardioplegia.
abstract: The study aimed at checking effects exerted by captopril (C) on human myocardial ACE system as well as the role played by tissue ACE inhibition in reducing reperfusion damage. A human experimental model was used during cardioplegia due to aorto-coronary-by-pass (CABG). Fifty-four patients with coronary artery disease affecting 3 vessels having suffered from acute myocardial infarction anterior (AMI-ant), homogeneous as far as ejection fraction (35-55%), number of grafts (3), clamping time, age and sex, were randomised in a double blind experiment, and were given captopril or placebo (P). A total of 4 mg/l Captopril was mixed into the cardioplegic solution with blood according to the method of Buckberg (Buckberg GD. J Thorac Cardiovasc Surg 1987; 93: 127-139). Eight samples (blood/perfusate) were obtained from each patients and norepinephrine (NE), epinephrine (E) were assayed using an HPLC technique. Angiotensin I was assayed by RIA. CK was also assayed (units/ml). Blood/perfusate samples were taken during CABG: (1) pre-pump; (2) pump sample; (3) pump preclamping; (4) coronary sinus; (5) coronary sinus sample during reperfusion; (6) coronary sinus during warm reperfusion; (7) after clamping sample; (8) after decanulation;
  
  
  RESULTS
  Captopril group (29 patients): angiotensin I: (1) 8.15; (2) 7.0; (3) 7.31; (4) 8.45; (5) 8.93; (6) 8.73; (7) 9.07; (8) 9.40; versus placebo: (1) 7.09, (2) 7.43; (3) 7.80; (4) 9.31; (5) 9.01; (6) 8.35; (7) 8.85; (8) 8.07 ng/ml, probability, not significant.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Cardiology, G.F. Ingrassia Hospital, Palermo, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Di Pasquale
authors.forename: S
authors.initials: S
authors.lastname: Paterna
authors.forename: M
authors.initials: M
authors.lastname: Valenza
authors.forename: L
authors.initials: L
authors.lastname: Valdes
authors.forename: V
authors.initials: V
authors.lastname: Albano
authors.forename: G
authors.initials: G
authors.lastname: Trombino
authors.forename: G
authors.initials: G
authors.lastname: Vitrano
authors.forename: S
authors.initials: S
authors.lastname: Cannizzaro
authors.forename: G
authors.initials: G
authors.lastname: Licata
authors.forename: R
authors.initials: R
authors.lastname: Albiero
mesh_terms: D000803:Angiotensin I / Q000097:blood; D002216:Captopril / Q000627:therapeutic use*; D001026:Coronary Artery Bypass; D003402:Creatine Kinase / Q000097:blood; D004311:Double-Blind Method; D004837:Epinephrine / Q000097:blood; D005260:Female; D006324:Heart Arrest, Induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D015428:Myocardial Reperfusion Injury / Q000517:prevention & control*; D009638:Norepinephrine / Q000097:blood
chemical_list: D000803:Angiotensin I; D002216:Captopril; D003402:Creatine Kinase; D009638:Norepinephrine; D004837:Epinephrine